Your session is about to expire
← Back to Search
AG-73305 for Diabetic Macular Edema
Study Summary
This trial is testing a new drug for people with diabetes who have a condition called diabetic macular edema. The drug is given as a shot into the eye, and different doses are being tested to see how well it works.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My diabetes is not under control, with an A1c level over 12%.My blood pressure is not controlled and is very high.I have not used Ozurdex in the last 6 months or Iluvien in my study eye.I currently have an infection in one or both of my eyes.My eye condition involves swelling in the center with a thickness of 325 μm or more.I haven't had VEGF treatment in my eye for 6-8 weeks.I have been diagnosed with diabetes (Type 1 or Type 2).I am 18 years old or older.My vision loss due to DME falls within the specified range for the study.I have long-term kidney disease.My eye pressure is high (>25 mmHg) despite using glaucoma medications, or I need more than 2 medications to control it.
- Group 1: Cohort 1
- Group 2: Cohort 2
- Group 3: Cohort 3
- Group 4: Cohort 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are actively participating in the experiment?
"Affirmative, the clinical trials website confirms that this medical experiment is still open to applicants. It was initially published on June 9th 2022 and has been recently revised as of June 29th 2022. 25 individuals need to be enrolled from 2 centres."
What potential risks have been identified with AG-73305?
"Due to the lack of efficacy data and presence of safety information, our team has assigned AG-73305 a score of 2 on the 1-3 scale."
Is this experiment presently open for enrollment?
"Affirmative. According to clinicaltrials.gov, this medical research is actively seeking volunteers after being posted on June 9th 2022 and last edited on June 29th of the same year. The trial requires 25 participants from 2 sites."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger